The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShearwater Regulatory News (SWG)

Share Price Information for Shearwater (SWG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.00
Bid: 43.00
Ask: 45.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.651%)
Open: 44.00
High: 44.00
Low: 44.00
Prev. Close: 44.00
SWG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sch 1 - Shearwater Group Plc

1 Oct 2018 07:30

RNS Number : 4035C
AIM
01 October 2018
 

 

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Shearwater Group plc

 

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

Registered office - 22 Great James Street, London, WC1N 3ES

Trading address - Octagon Point, 5 Cheapside, London EC2V 6AA

 

COUNTRY OF INCORPORATION:

England and Wales

 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

https://www.theshearwatergroup.co.uk/

 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

 

Shearwater is an AIM-quoted company focused on building a UK based group providing digital resilience solutions.

 

The Company's aim is to acquire and develop information security and cyber security companies with a leading product, solution or service capability whose full potential can be unlocked through active management and capital investment.

 

Shearwater Group plc is the holding company for the group's wholly-owned trading companies, including SecurEnvoy Limited, Xcina Limited and, following re-admission, Brookcourt Solutions Limited ("Brookcourt").

 

Brookcourt is a multi-award winning, UK-based cyber security company, focusing on the provision of networking and cyber security solutions to corporate and public sector organisations. Brookcourt's solutions help its customers by providing all and any aspect of the full end to end network design, supply, integration, support and managed services that a customer needs to assure and secure their network infrastructure in an advanced threat landscape. Brookcourt is headquartered in Redhill in Surrey, with a second office located in Bracknell and currently employs 28 people across both sites.

 

The Transaction consideration is £15.15m cash and £15.15m in Shearwater shares. This consideration structure has been amended from the earlier announced split of £22.95m cash and £7.35m in Shearwater shares. The cash consideration component of the Transaction will be financed through a fundraising consisting of a placing and an open offer (the "Fundraising"). The Transaction and the Fundraising are inter-conditional.

 

The Transaction constitutes a reverse takeover under AIM Rule 14 and accordingly, the Company will seek readmission ("Admission") of its shares to trading on AIM of the London Stock Exchange.

 

The Transaction and associated fundraising will be subject to the passing of relevant resolutions at the Company's general meeting to be confirmed.

 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

 

Up to 1,906,854,786 Ordinary shares of 1 penny each ("Ordinary Shares") (assuming full take up under the Open Offer).

 

There will be no Ordinary Shares held in treasury and no restrictions on the transfer of the securities.

 

CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Gross capital raised on admission - Placing of £16.7m and up to additional £1m under open offer.

 

Implied market capitalisation - £68.6m

 

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

Before Admission 45.8 per cent.

 

Post Admission 40.3 per cent.

 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

None

 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Directors

 

David Jeffreys Williams (Chairman)

 

Michael Joseph ("Mo") Stevens (Chief Executive Officer)

 

Robin Simon Southwell (Non-Executive Director)

 

Stephen Robert Ball (Non-Executive Director)

 

Giles Kirkley Willits (Non-Executive Director)

 

 

Proposed Directors

 

Paul John McFadden (Interim Finance Director)

 

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Significant Shareholder

30 June 2018

After Admission1

Phil Higgins

-

11.03%

Dene Stacy

-

11.03%

David Williams

12.04%

6.72%

Schroders

10.91%

8.61%

Stephen Watts

8.97%

4.68%

Andrew Kemshall

8.77%

4.58%

Killik & Co

5.48%

7.21%

Columbia Threadneedle

4.43%

3.19%

Canaccord Genuity WM

3.77%

3.42%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1. Assumes full take up of open offer.

 

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

N/A

 

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i) 31 March

(ii) Target's information is to 31 December 2017. Shearwater's information is audited annual financial information to 31 March 2018.

(iii) Half year report for the six months ended 30 September 2018 published by 31 December 2018. Annual report for the year ended 31 March 2019 published by 30 September 2019. Half year report for the six months ended 30 September 2019 published by 31 December 2019.

 

 

EXPECTED ADMISSION DATE:

17 October 2018

 

NAME AND ADDRESS OF NOMINATED ADVISER:

Cenkos Securities

6.7.8 Tokenhouse Yard

London EC2R 7AS

 

NAME AND ADDRESS OF BROKER:

Cenkos Securities

6.7.8 Tokenhouse Yard

London EC2R 7AS

 

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

The admission document containing full details about the Group and the admission of its ordinary shares will be available from the registered office of the Company, being 22 Great James Street, London WC1N 3ES, and on the Company's website www.theshearwatergroup.co.uk.

THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

QCA

 

DATE OF NOTIFICATION:

1 October 2018

 

NEW/ UPDATE:

New

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PAAUWAVRWUAKUAR
Date   Source Headline
3rd Apr 20247:00 amRNSFY24 Trading Update
4th Jan 20247:00 amRNSContract Wins
22nd Nov 20237:00 amRNSInterim Results
21st Nov 202311:18 amRNSChange of Nominated Adviser and Broker
20th Nov 20231:19 pmRNSBoard Update
3rd Nov 202310:12 amRNSNotice of Results and Board Appointment
10th Oct 20237:00 amRNSInterim CFO Appointment
5th Sep 20237:00 amRNSFinal Results
25th Aug 20237:00 amRNSUpdate re FY23 Results and Trading Update
8th Jun 20237:00 amRNSTrading Update
5th May 20232:33 pmRNSHolding(s) in Company
18th Apr 20238:58 amRNSDirector/PDMR Shareholding
17th Apr 202312:51 pmRNSDirector/PDMR Shareholding
6th Apr 20237:00 amRNSDirector/PDMR Shareholding
31st Mar 20232:05 pmRNSSecond Price Monitoring Extn
31st Mar 20232:00 pmRNSPrice Monitoring Extension
31st Mar 20239:05 amRNSSecond Price Monitoring Extn
31st Mar 20239:00 amRNSPrice Monitoring Extension
31st Mar 20237:00 amRNSTrading Update
8th Mar 20233:30 pmRNSHolding(s) in Company
28th Feb 20231:26 pmRNSExercise of Options
8th Dec 20222:34 pmRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSDirector/PDMR Shareholding
1st Dec 20222:40 pmRNSDirector/PDMR Shareholding
29th Nov 20222:05 pmRNSSecond Price Monitoring Extn
29th Nov 20222:00 pmRNSPrice Monitoring Extension
29th Nov 20227:00 amRNSResults for the six months ended 30 September 2022
23rd Nov 20227:00 amRNSAdviser Update
17th Nov 20227:00 amRNSNotice of Results and Presentation to Investors
7th Oct 20228:32 amRNSHolding(s) in Company
5th Oct 20227:00 amRNSDirector/PDMR Shareholding
21st Sep 20227:00 amRNSResult of AGM
5th Sep 202210:00 amRNSNotice of AGM
1st Sep 20227:00 amRNSContract Renewal
25th Aug 20227:00 amRNSPosting of Annual Report
23rd Aug 20222:43 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSFinal Results
22nd Jul 20227:00 amRNSNotice of Results and Presentation to Investors
6th Jun 20224:41 pmRNSSecond Price Monitoring Extn
6th Jun 20224:36 pmRNSPrice Monitoring Extension
27th Apr 20227:00 amRNSYear End Trading Update
13th Apr 20227:00 amRNSContract Win
24th Mar 20227:00 amRNSContract Win
22nd Mar 20224:37 pmRNSExercise of options
17th Mar 20227:00 amRNSContract Win
3rd Mar 20224:26 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSGrant of Options and Director/PDMR Dealing
27th Jan 20227:00 amRNSContract Renewals
11th Jan 20227:00 amRNSContract Win
14th Dec 20217:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.